Suppr超能文献

BRD4通过Jagged1/Notch1信号通路调控乳腺癌转移。

BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling.

作者信息

Andrieu Guillaume, Tran Anna H, Strissel Katherine J, Denis Gerald V

机构信息

Cancer Center, Boston University School of Medicine, Boston, Massachusetts.

Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts.

出版信息

Cancer Res. 2016 Nov 15;76(22):6555-6567. doi: 10.1158/0008-5472.CAN-16-0559. Epub 2016 Sep 20.

Abstract

The bromodomain and extraterminal (BET) proteins are epigenetic "readers" of acetylated histones in chromatin and have been identified as promising therapeutic targets in diverse cancers. However, it remains unclear how individual family members participate in cancer progression and small molecule inhibitors such as JQ1 can target functionally independent BET proteins. Here, we report a signaling pathway involving BRD4 and the ligand/receptor pair Jagged1/Notch1 that sustains triple-negative breast cancer migration and invasion. BRD4, but not BRD2 or BRD3, regulated Jagged1 expression and Notch1 signaling. BRD4-selective knockdown suppressed Notch1 activity and impeded breast cancer migration and invasion. BRD4 was required for IL6-stimulated, Notch1-induced migration and invasion, coupling microenvironment inflammation with cancer propagation. Moreover, in patients, BRD4 and Jagged1 expression positively correlated with the presence of distant metastases. These results identify a BRD4/Jagged1/Notch1 signaling pathway that is critical for dissemination of triple-negative breast cancer. Cancer Res; 76(22); 6555-67. ©2016 AACR.

摘要

溴结构域和额外末端(BET)蛋白是染色质中乙酰化组蛋白的表观遗传“读取器”,已被确定为多种癌症中有前景的治疗靶点。然而,尚不清楚单个家族成员如何参与癌症进展,以及诸如JQ1之类的小分子抑制剂如何靶向功能独立的BET蛋白。在此,我们报告了一条涉及BRD4以及配体/受体对Jagged1/Notch1的信号通路,该通路维持三阴性乳腺癌的迁移和侵袭。BRD4而非BRD2或BRD3调节Jagged1表达和Notch1信号传导。BRD4选择性敲低抑制了Notch1活性,并阻碍了乳腺癌的迁移和侵袭。BRD4是IL6刺激、Notch1诱导的迁移和侵袭所必需的,它将微环境炎症与癌症传播联系起来。此外,在患者中,BRD4和Jagged1表达与远处转移的存在呈正相关。这些结果确定了一条对三阴性乳腺癌扩散至关重要的BRD4/Jagged1/Notch1信号通路。《癌症研究》;76(22);6555 - 67。©2016美国癌症研究协会。

相似文献

1
BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling.
Cancer Res. 2016 Nov 15;76(22):6555-6567. doi: 10.1158/0008-5472.CAN-16-0559. Epub 2016 Sep 20.
4
Hsa-miR-599 inhibits breast cancer progression via BRD4/Jagged1/Notch1 axis.
J Cell Physiol. 2022 Jan;237(1):523-531. doi: 10.1002/jcp.30548. Epub 2021 Aug 20.
5
6
BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition.
Mol Cancer Res. 2018 Apr;16(4):580-586. doi: 10.1158/1541-7786.MCR-17-0568. Epub 2018 Feb 7.
8
Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets.
Front Endocrinol (Lausanne). 2023 Jan 30;14:1089531. doi: 10.3389/fendo.2023.1089531. eCollection 2023.
9
Brucine inhibits bone metastasis of breast cancer cells by suppressing Jagged1/Notch1 signaling pathways.
Chin J Integr Med. 2017 Feb;23(2):110-116. doi: 10.1007/s11655-016-2647-2. Epub 2016 Dec 29.

引用本文的文献

1
Beyond small molecules: advancing MYC-targeted cancer therapies through protein engineering.
Transcription. 2025 Feb;16(1):67-85. doi: 10.1080/21541264.2025.2453315. Epub 2025 Jan 29.
2
BRD4: an effective target for organ fibrosis.
Biomark Res. 2024 Aug 30;12(1):92. doi: 10.1186/s40364-024-00641-6.
3
BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression.
Oncogene. 2024 Sep;43(39):2914-2926. doi: 10.1038/s41388-024-03121-1. Epub 2024 Aug 20.
4
Prioritizing drug targets by perturbing biological network response functions.
PLoS Comput Biol. 2024 Jun 27;20(6):e1012195. doi: 10.1371/journal.pcbi.1012195. eCollection 2024 Jun.
5
Sequential Inhibition of PARP and BET as a Rational Therapeutic Strategy for Glioblastoma.
Adv Sci (Weinh). 2024 Aug;11(30):e2307747. doi: 10.1002/advs.202307747. Epub 2024 Jun 19.
8
Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review).
Oncol Rep. 2024 Jun;51(6). doi: 10.3892/or.2024.8733. Epub 2024 Apr 12.
10
Effects of bromodomain and extra-terminal inhibitor JQ1 and interleukin-6 on breast cancer cells.
Mol Biol Rep. 2023 Oct;50(10):8319-8328. doi: 10.1007/s11033-023-08718-5. Epub 2023 Aug 17.

本文引用的文献

1
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Nature. 2016 Jan 21;529(7586):413-417. doi: 10.1038/nature16508. Epub 2016 Jan 6.
2
Notch signaling: an emerging therapeutic target for cancer treatment.
Cancer Lett. 2015 Dec 1;369(1):20-7. doi: 10.1016/j.canlet.2015.07.048. Epub 2015 Sep 1.
5
BRD4 inhibitor inhibits colorectal cancer growth and metastasis.
Int J Mol Sci. 2015 Jan 16;16(1):1928-48. doi: 10.3390/ijms16011928.
6
Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways.
Cell. 2014 Oct 23;159(3):499-513. doi: 10.1016/j.cell.2014.09.051.
7
The notch ligand JAGGED1 as a target for anti-tumor therapy.
Front Oncol. 2014 Sep 25;4:254. doi: 10.3389/fonc.2014.00254. eCollection 2014.
10
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11365-70. doi: 10.1073/pnas.1411701111. Epub 2014 Jul 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验